These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38743192)

  • 1. Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review.
    Richmond DiBello J; Raziano VT; Liu X; Puenpatom A; Peebles K; Khan NF; Hill DD
    Infect Dis Ther; 2024 Jun; 13(6):1177-1198. PubMed ID: 38743192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel.
    Weil C; Bergroth T; Eisenberg A; Whiteside YO; Caraco Y; Tene L; Chodick G
    Epidemiologia (Basel); 2023 Aug; 4(3):309-321. PubMed ID: 37606468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.
    Goswami H; Alsumali A; Jiang Y; Schindler M; Duke ER; Cohen J; Briggs A; Puenpatom A
    Pharmacoeconomics; 2022 Jul; 40(7):699-714. PubMed ID: 35779197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting.
    Mutoh Y; Umemura T; Nishikawa T; Kondo K; Nishina Y; Soejima K; Noguchi Y; Bando T; Ota S; Shimahara T; Hirota S; Hagimoto S; Takei R; Fukihara J; Sasano H; Yamano Y; Yokoyama T; Kataoka K; Matsuda T; Kimura T; Ichihara T; Kondoh Y
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
    Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
    BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis.
    Huang C; Lu TL; Lin L
    Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting.
    Kwok WC; Tsoi MF; Leung SHI; Tsui CK; Tam TCC; Ho JCM; Lam DCL; Ip MSM; Ho PL
    Viruses; 2023 Feb; 15(3):. PubMed ID: 36992319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
    Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
    J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effectiveness of oral antiviral agents in older patients with COVID-19 based on real-world data.
    Tsai YW; Wu JY; Liu TH; Chuang MH; Hsu WH; Huang PY; Lai CC; Tsai KT; Shiue YL
    J Med Virol; 2023 Jun; 95(6):e28869. PubMed ID: 37322616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.
    Dlouhý P; Mucha C; Mokrá L; Kuhn M; Hrdlickova L; Arnet U; Whiteside Y
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673576
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic.
    Suzuki Y; Shibata Y; Minemura H; Nikaido T; Tanino Y; Fukuhara A; Kanno R; Saito H; Suzuki S; Inokoshi Y; Sando E; Sakuma H; Kobayashi T; Kume H; Kamimoto M; Aoki H; Takama A; Iizuka T; Kamiyama T; Nakayama M; Saito K; Tanigawa K; Sato M; Waragai Y; Kambe T; Kanzaki N; Azuma T; Okamoto H; Sakamoto K; Nakamura Y; Ohtani H; Waragai M; Maeda S; Ishida T; Sugino K; Abe W; Tsukada Y; Lee T; Yamada R; Sato R; Onuma T; Tomita H; Saito M; Watanabe N; Rikimaru M; Kawamata T; Morimoto J; Togawa R; Sato Y; Saito J; Kanazawa K; Hamaguchi S; Iseki K
    Clin Exp Med; 2023 Oct; 23(6):2715-2723. PubMed ID: 36469171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review.
    Drysdale M; Gibbons DC; Singh M; Rolland C; Lavoie L; Skingsley A; Lloyd EJ
    Infection; 2024 Feb; 52(1):1-17. PubMed ID: 37776474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis.
    Najjar-Debbiny R; Gronich N; Weber G; Khoury J; Amar M; Stein N; Goldstein LH; Saliba W
    Clin Infect Dis; 2023 Feb; 76(3):453-460. PubMed ID: 36130189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.